Shares of Anadys Pharmaceuticals jumped 22 percent on the news that the FDA had approved a mid-stage study of its hepatitis C drug. The approval gives researchers a green light to begin recruiting 90 patients who will receive either a 200 mg or 400 mg dose of ANA598 or a placebo. Analysts have been closely watching the progress of Anadys' lead therapy, highlighting safety concerns after three patients dropped out of an earlier trial after developing a rash. Report